January 3, 2017 / 12:52 PM / 8 months ago

BRIEF-Marinus Pharmaceuticals receives FDA orphan drug designation for Ganaxolone to treat Fragile X Syndrome

Jan 3 (Reuters) - Marinus Pharmaceuticals Inc :

* Marinus Pharmaceuticals receives FDA orphan drug designation for Ganaxolone to treat Fragile X Syndrome Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below